-

12:53:29 PM

ETON Stock News

ETON - Eton Pharmaceuticals Inc

12/20/21 7:30 AM

Nasdaq : ETON

low float

Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu® (carglumic acid)

RHEA-AI

positive

11/15/21 4:05 PM

Nasdaq : ETON

earningslow float

Eton Pharmaceuticals Reports Third Quarter Financial Results

Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the third quarter ended September 30, 2021. “Over the last

RHEA-AI

very positive

11/15/21 6:30 AM

Nasdaq : ETON

low float

Eton Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE®

Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that it has entered into a multi-year agreement with Tolmar Pharmaceuticals, Inc. to

RHEA-AI

neutral

11/08/21 6:00 AM

Nasdaq : ETON

fda approvallow float

Eton Pharmaceuticals and Azurity Pharmaceuticals, Inc. Announce FDA Approval of EPRONTIA™ (topiramate) Oral Solution

Eton Pharmaceuticals, Inc (Nasdaq: ETON) and Azurity Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EPRONTIA™

RHEA-AI

very positive

11/03/21 4:15 PM

Nasdaq : ETON

conferencesearningslow float

Eton Pharmaceuticals to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021

Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2021 financial and operating results on

RHEA-AI

neutral

10/28/21 7:30 AM

Nasdaq : ETON

acquisitionlow float

Eton Pharmaceuticals Announces Acquisition of Approved Orphan Drug Product Carglumic Acid

Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for

RHEA-AI

neutral

08/16/21 4:02 PM

Nasdaq : ETON

earningslow float

Eton Pharmaceuticals Reports Second Quarter Financial Results

Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the second quarter ended June 30, 2021. “During the second

RHEA-AI

neutral

08/03/21 4:05 PM

Nasdaq : ETON

conferencesearningslow float

Eton Pharmaceuticals to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021

Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2021 financial and operating results on

RHEA-AI

neutral

06/15/21 4:05 PM

Nasdaq : ETON

acquisitionlow float

Eton Pharmaceuticals Acquires U.S. and Canadian Rights to ZENEO® Hydrocortisone Autoinjector

Expands Eton’s Adrenal Insufficiency Orphan Drug Portfolio ZENEO® Hydrocortisone is Expected to be the First and Only Hydrocortisone Autoinjector for Patients Requiring Emergency Hydrocortisone Proprietary ZENEO® Needleless Device is Covered by 24 U.S. Patents Extending as Far as 2037 DEER PARK,

RHEA-AI

neutral

06/15/21 10:37 AM

Nasdaq : ETON

fda approvallow float

Eton Pharmaceuticals Announces FDA Approval of Rezipres® (Ephedrine Hydrochloride Injection)

Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres ® (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting

RHEA-AI

very positive